Tag: Edrophonium

Though once a vital diagnostic tool for myasthenia gravis, the FDA discontinued edrophonium in the U.S. for this purpose in 2018, citing a high rate of false-positive results. The function of edrophonium, however, stems from its mechanism as a short-acting acetylcholinesterase inhibitor.

In 2018, the U.S. Food and Drug Administration (FDA) discontinued the use of edrophonium, effectively ending the era of the Tensilon test as a diagnostic tool for myasthenia gravis. This decision was driven by the test's inherent limitations and the advent of safer, more accurate diagnostic methods.